natgillin/translations-raw huggingface dataset:
Preclinical studies of apixaban in animal models have demonstrated antithrombotic efficacy in the prevention of arterial and venous thrombosis at doses that preserved haemostasis.
Predklinične študije na živalskih modelih so pokazale antitrombotično učinkovitost apiksabana pri preprečevanju arterijske in venske tromboze pri odmerkih, ki ohranijo hemostazo.
Patients were randomized 1:1 to apixaban or to heparin and/or VKA for the prevention of cardiovascular events.
Bolnike so randomizirali 1 : 1 v skupino z apiksabanom ali v skupino s heparinom in/ali AVK za preprečevanje srčno-žilnih dogodkov.
Safety and efficacy of Eliquis have not been studied in patients with prosthetic heart valves, with or without atrial fibrillation.
Varnosti in učinkovitosti zdravila Eliquis pri bolnikih s protetičnimi srčnimi zaklopkami z atrijsko fibrilacijo ali brez nje niso raziskovali.
After an operation to the hip or knee you may be at a higher risk of developing blood clots in your leg veins.
Po operaciji kolka ali kolena se lahko poveča tveganje za razvoj krvnih strdkov v venah nog.
Apixaban is metabolised mainly via CYP3A4/5 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2.
Apiksaban se v glavnem presnavlja preko CYP3A4/5 in le v manjši meri preko CYP1A2, 2C8, 2C9, 2C19 ter 2J2.
• Transfer all the powder carefully into a suitable container then mix the powder with a little e.g., 30 mL (2 tablespoons), water or one of the other liquids mentioned above to make a mixture.
• Previdno prenesite ves prašek v primeren vsebnik in ga zmešajte z malo, npr. 30 ml (2 jedilni žlici), vode ali ene od drugih zgoraj naštetih tekočin, da dobite mešanico.
The adjudicated major bleeding and CRNM bleeding at any anatomical site were generally lower in the apixaban group as compared to the enoxaparin/warfarin group.
Obravnavane večje krvavitve in klinično pomembne manjše krvavitve (KPMK) na kateremkoli anatomskem mestu so bile na splošno redkejše v skupini z apiksabanom v primerjavi s skupino z enoksaparinom/varfarinom.
In a clinical trial of patients with atrial fibrillation, concomitant use of ASA increased the major bleeding risk on apixaban from 1.8% per year to 3.4% per year and increased the bleeding risk on warfarin from 2.7% per year to 4.6% per year.
V kliničnem preskušanju pri bolnikih z atrijsko fibrilacijo je sočasna uporaba acetilsalicilne kisline povečala tveganje za večje krvavitve ob uporabi apiksabana z 1,8 % na leto na 3,4 % na leto, tveganje za krvavitve ob uporabi varfarina pa z 2,7 % na leto na 4,6 % na leto.
Apixaban is a substrate of transport proteins, P-gp and breast cancer resistance protein (BCRP).
Apiksaban je substrat za prenašalno beljakovino P-gp in rezistentno beljakovino, izolirano pri raku dojke (BCRP; “breast cancer resistance protein”).
Apixaban has no direct effects on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin.
Apiksaban nima neposrednega učinka na agregacijo trombocitov, vendar pa posredno zavira agregacijo trombocitov, ki jo povzroča trombin.
The mean age was 56.7 years and 91.7% of randomised patients had unprovoked VTE events.
Povprečna starost je bila 56,7 leta, 91,7 % randomiziranih bolnikov pa je imelo neizzvane dogodke VTE.
Findings from a population pharmacokinetic analysis in patients who received apixaban were generally consistent with the phase I results.
Ugotovitve analize populacijske farmakokinetike pri bolnikih, ki so se zdravili z apiksabanom, se na splošno skladajo z rezultati študij I. faze.
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from apixaban therapy.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/neuvedbo zdravljenja z apiksabanom.
Apixaban efficacy for prevention of a recurrence of a VTE was maintained across subgroups, including age, gender, BMI, and renal function.
Učinkovitost apiksabana pri preprečevanju ponovne VTE je ostala nespremenjena v vseh podskupinah, glede na starost, spol, ITM in delovanje ledvic.
Common reasons for unsuitability for VKA therapy in the AVERROES study included unable/unlikely to obtain INRs at requested intervals (42.6%), patient refused treatment with VKA (37.4%), CHADS2 score = 1 and physician did not recommend VKA (21.3%), patient could not be relied on to adhere to VKA medicinal product instruction (15.0%), and difficulty/expected difficulty in contacting patient in case of urgent dose change (11.7%).
Običajni vzroki za neprimernost zdravljenja z AVK v študiji AVERROES so bili naslednji: nezmožnost ali zelo majhna možnost za doseg vrednosti INR v zahtevanih območjih (42,6 %); bolniki so zavračali zdravljenje z AVK (37,4 %); ocena po merilih CHADS2 = 1, tako da zdravnik VKA ni priporočil (21,3 %); pri bolniku se ni bilo mogoče zanesti na to, da se bo držal navodil za zdravljenje z AVK (15,0 %); in težave oziroma pričakovane težave pri vzpostavljanju stika z bolnikom v primeru nujne spremembe odmerka (11,7 %).
In the toxicity studies little to no increase of bleeding tendency was found.
V študijah toksičnosti niso zaznali povečanega nagnjenja k pojavu krvavitev ali pa je bilo nagnjenje le malenkostno večje.
In patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp the following recommendations apply (see section 4.5):
Pri bolnikih, ki prejemajo sočasno sistemsko zdravljenje z močnimi induktorji tako CYP3A4 kot P-gp, veljajo naslednja priporočila (glejte poglavje 4.5):
If a dose is missed, the patient should take Eliquis immediately and then continue with twice daily intake as before.
Če bolnik pozabi vzeti odmerek zdravila Eliquis, ga mora vzeti takoj ko se spomni, nato pa nadaljevati z jemanjem zdravila dvakrat na dan, kot pred tem.
If cardioversion is required before 5 doses of apixaban can be administered, a 10 mg loading dose should be given, followed by 5 mg twice daily.
Če je kardioverzija potrebna, preden je mogoče dati 5 odmerkov apiksabana, je treba uporabiti 10 mg polnilni odmerek, čemur sledi 5 mg dvakrat na dan.
The pharmacokinetic /pharmacodynamic (PK/PD) relationship between apixaban plasma concentration and several PD endpoints (anti-FXa activity, INR, PT, aPTT) has been evaluated after administration of a wide range of doses (0.5 - 50 mg).
Razmerje med farmakokinetiko/farmakodinamiko (PK/PD) med plazemskimi koncentracijami apiksabana in različnimi farmakodinamičnimi opazovanimi dogodki (aktivnost anti-FXa, INR, PČ, PTČ) so ovrednotili pri širokem razponu uporabljenih odmerkov (0,5 do 50 mg).
Always take this medicine exactly as your doctor or pharmacist has told you.
Zdravilo jemljite redno, kot vam je naročil zdravnik.
Interaction with other medicinal products affecting haemostasis Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section 4.3).
Interakcije z drugimi zdravili, ki vplivajo na hemostazo Zaradi povečanega tveganja za krvavitve je sočasno zdravljenje s katerimkoli drugim antikoagulantom kontraindicirano (glejte poglavje 4.3).
For patients randomised to warfarin, the mean percentage of time in therapeutic range (INR 2.0-3.0) was 60.9.
Pri bolnikih, randomiziranih v skupino z varfarinom, je povprečen odstotek časa v terapevtskem območju (INR 2,0-3,0) znašal 60,9.
Inside the Eliquis pack together with the package leaflet you will find a Patient Alert Card or your doctor might give you a similar card.
V škatlici zdravila Eliquis se skupaj z navodilom za uporabo nahaja opozorilna kartica za bolnika; podobno kartico vam bo morda dal tudi zdravnik.
If you miss a dose, take it as soon as you remember and continue to follow your dosing schedule.
Če ste pozabili vzeti odmerek, tableto vzemite takoj, ko se spomnite, in nadaljujte z običajnim jemanjem zdravila.
In vitro apixaban studies showed no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 or CYP3A4 (IC50 > 45 µM) and weak inhibitory effect on the activity of CYP2C19 (IC50 > 20 µM) at concentrations that are significantly greater than peak plasma concentrations observed in patients.
Pri in vitro študijah niso ugotovili zaviralnega učinka apiksabana na aktivnost CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 ali CYP3A4 (IC50 > 45 M) in šibek zaviralni učinek na aktivnost CYP2C19 (IC50 > 20 M) pri koncentracijah, ki so bile pomembno večje od največjih plazemskih koncentracij pri človeku.
Increases in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone.
Povečanja vrednosti testov strjevanja krvi (PČ, INR in aPTČ) so bila skladna z učinki samostojno uporabljenega apiksabana.
The next dose of apixaban may be given at least 5 hours after catheter removal.
Bolnik sme vzeti naslednji odmerek apiksabana najmanj 5 ur po odstranitvi katetra.
In patients with severe renal impairment (creatinine clearance 15-29 mL/min) the following recommendations apply (see sections 4.4 and 5.2):
Pri bolnikih s hudo okvaro ledvic (očistek kreatinina 15-29 ml/min) veljajo naslednja priporočila (glejte poglavji 4.4 in 5.2):
The use of Eliquis may be associated with an increased risk of occult or overt bleeding from any tissue or organ, which may result in posthaemorrhagic anaemia.
Uporaba zdravila Eliquis je lahko povezana z večjim tveganjem za pojav prikrite ali manifestne krvavitve iz kateregakoli tkiva ali organa.
Treatment with Eliquis does not require routine monitoring of exposure.
Pri zdravljenju z apiksabanom izpostavljenosti ni treba rutinsko spremljati.
Body weight Low body weight (< 60 kg) may increase haemorrhagic risk (see section 5.2).
Telesna masa Majhna telesna masa (< 60 kg) lahko poveča tveganje za krvavitve (glejte poglavje 5.2).
• Hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 5.2).
• Bolezen jeter, ki je povezana z motnjami strjevanja krvi in klinično pomembnim tveganjem za krvavitve (glejte poglavje 5.2).
Prevention of stroke and systemic embolism in adult patients with NVAF, with one or more risk factors (NVAF)
Preprečevanje možganske kapi in sistemske embolije pri odraslih bolnikih z NVAF in enim ali več dejavniki tveganja (NVAF)
Renal impairment had no evident effect on the relationship between apixaban plasma concentration and anti-FXa activity.
Okvara ledvic nima očitnih vplivov na razmerje med koncentracijami apiksabana v plazmi in aktivnostjo anti-FXa.
Inducers of CYP3A4 and P-gp
Induktorji CYP3A4 in P-gp
Apixaban can be taken with or without food.
Apiksaban se lahko jemlje skupaj s hrano ali brez nje.
Major*
Večje*
Fertility Studies in animals dosed with apixaban have shown no effect on fertility (see section 5.3).
Pri študijah na živalih, ki so prejemale apiksaban, vpliva na plodnost niso ugotovili (glejte poglavje 5.3).
If a blood clot travels from your leg to your lungs, it can block blood flow causing breathlessness, with or without chest pain.
Če krvni strdek iz noge zaide v pljuča, lahko prepreči pretok krvi v pljučih in povzroči težko dihanje, ki ga lahko spremlja bolečina v prsnem košu ali pa tudi ne.
The first dose of apixaban was given 12 to 24 hours post-surgery, whereas enoxaparin was started 9 to 15 hours prior to surgery.
Bolniki so prvi odmerek apiksabana prejeli od 12 do 24 ur po operaciji, prvi odmerek enoksaparina pa od 9 do 15 ur pred operacijo.
Key Elements of the Prescriber Guide:
Ključni elementi navodila za zdravnike, ki predpisujejo zdravilo:
EMANATE, an open-label, multi-center study, enrolled 1500 patients who were either oral anticoagulant naïve or pre-treated less than 48 hours, and scheduled for cardioversion for NVAF.
EMANATE je bila odprta multicentrična študija, v katero so vključili 1.500 bolnikov, naročenih na kardioverzijo zaradi NVAF, ki bodisi predhodno niso prejeli peroralnega antikoagulacijskega zdravljenja bodisi so se predhodno zdravili manj kot 48 ur.
Eliquis contains the active substance apixaban and belongs to a group of medicines called anticoagulants.
Učinkovina zdravila Eliquis je apiksaban, ki sodi v skupino zdravil, imenovano antikoagulanti.
Eliquis should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding.
Z uporabo zdravila Eliquis je treba prenehati najmanj 24 ur pred načrtovano operacijo ali invazivnimi postopki, pri katerih je prisotno majhno tveganje za krvavitve.
Reversal of Eliquis pharmacodynamic effects, as demonstrated by changes in the thrombin generation assay, was evident at the end of infusion and reached baseline values within 4 hours after the start of a 4-factor PCC 30 minute infusion in healthy subjects.
Pri zdravih preskušancih so ugotovili izgubo farmakodinamičnih učinkov zdravila Eliquis, dokazano s spremembami vrednosti testov tvorbe trombina ob koncu infundiranja 30 minutne infuzije, pri čemer je bila izhodiščna vrednost dosežena v 4 urah po začetku infundiranja 4-faktorskih pripravkov PCC.
Alu-PVC/PVdC blisters.
Pretisni omoti iz Alu-PVC/PVdC.
All-cause death occurred in 2 patients (0.27%) in the apixaban group and 1 patient (0.13%) in the heparin and/or VKA group.
Do smrti iz vseh vzrokov je prišlo pri 2 bolnikih (0,27 %) v skupini z apiksabanom in pri 1 bolniku (0,13 %) v skupini s heparinom in/ali AVK.
If your abnormal heartbeat needs to be restored to normal by a procedure called cardioversion, take Eliquis at the times your doctor tells you, to prevent blood clots in blood vessels in your brain and other blood vessels in your body.
Če imate nenormalen srčni utrip in za povrnitev na normalnega potrebujete postopek, imenovan kardioverzija, jemljite zdravilo Eliquis takrat, kot vam je to predpisal zdravnik, da preprečite nastanek krvnih strdkov v možganskih žilah in drugih žilah v telesu.
• The active substance is apixaban.
• Učinkovina je apiksaban.
The signs, symptoms, and severity will vary according to the location and degree or extent of the bleeding (see sections 4.4 and 5.1).
Posledično se lahko razvije posthemoragična anemija, katere znaki, simptomi in resnost so odvisni od mesta in stopnje ali obsega krvavitve (glejte poglavji 4.4 in 5.1).
Eliquis should be used with caution when coadministered with SSRIs/SNRIs or NSAIDs (including acetylsalicylic acid) because these medicinal products typically increase the bleeding risk.
Pri sočasni uporabi zdravila Eliquis in SSRI/SNRI ali NSAID (vključno z acetilsalicilno kislino) je potrebna previdnost, saj je za ta zdravila značilno, da povečajo tveganje za krvavitve.
If bleeding occurs, surgery, blood transfusions, or other treatments that may reverse anti-factor Xa activity may be required.
V primeru krvavitve bo morda potrebna operacija, transfuzija krvi ali zdravljenje z drugimi zdravili, ki lahko zaustavijo zaviralno delovanje na faktor Xa.
* There were no occurrences of generalized pruritus in CV185057 (long term prevention of VTE)
* V študiji CV185057 (dolgotrajno preprečevanje VTE) niso opazili pojava generaliziranega pruritusa.
For patients who are unable to swallow whole tablets, Eliquis tablets may be crushed and suspended in water, or 5% dextrose in water (D5W), or apple juice or mixed with apple puree and immediately administered orally (see section 5.2).
Bolnikom, ki niso zmožni pogoltniti celih tablet, lahko tablete zdravila Eliquis zdrobimo in suspendiramo v vodi, 5 % glukozi in vodi (D5W) ali jabolčnem soku, lahko pa jih zmešamo z jabolčno čežano, nato pa morajo pripravljeno nemudoma zaužiti (glejte poglavje 5.2).
* Noninferior compared to enoxaparin/warfarin (p-value < 0.0001)
* enakovreden v primerjavi z enoksaparinom/varfarinom (vrednost p < 0,0001)
Patients undergoing catheter ablation (NVAF) Patients can continue apixaban use while undergoing catheter ablation (see sections 4.3, 4.4 and 4.5).
Bolniki s katetrsko ablacijo (NVAF) Med katetrsko ablacijo lahko bolniki še naprej uporabljajo apiksaban (glejte poglavja 4.3, 4.4 in 4.5).
Included in this total were 1,262 patients (618 in the apixaban group) of age 75 or older, 1,004 patients (499 in the apixaban group) with low body weight (≤ 60 kg), 1,495 patients (743 in the apixaban group) with BMI ≥ 33 kg/m2, and 415 patients (203 in the apixaban group) with moderate renal impairment.
Med vsemi vključenimi bolniki je bilo 1.262 bolnikov (618 v skupini z apiksabanom), ki so bili stari 75 let ali starejši, 1.004 bolniki (499 v skupini z apiksabanom), ki so imeli majhno telesno maso (≤ 60 kg), 1.495 bolnikov (743 v skupini z apiksabanom), ki so imeli indeks telesne mase ≥ 33 kg/m2 in 415 bolnikov (203 v skupini z apiksabanom), ki so imeli zmerno okvaro ledvic.
This condition (pulmonary embolism) can be life-threatening and requires immediate medical attention.
To stanje (imenovano tudi pljučna embolija) lahko ogrozi življenje in zahteva takojšnje zdravljenje.
Yellow iron oxide (E172)
triacetin rumeni železov oksid (E172)
Therefore, apixaban is not expected to alter the metabolic clearance of coadministered medicinal products that are metabolised by these enzymes.
Za apiksaban se torej ne pričakuje, da bi spremenil presnovni očistek sočasno uporabljenih zdravil, ki se presnavljajo preko teh encimov.
Therefore, haemodialysis is unlikely to be an effective means of managing apixaban overdose.
Zato hemodializa verjetno ne bo učinkovita pri obravnavanju prevelikega odmerjanja apiksabana.
10 film-coated tablets 20 film-coated tablets 60 film-coated tablets 60 x 1 film-coated tablets 100 x 1 film-coated tablets 168 film-coated tablets 200 film-coated tablets
10 filmsko obloženih tablet 20 filmsko obloženih tablet 60 filmsko obloženih tablet 60 x 1 filmsko obložena tableta 100 x 1 filmsko obložena tableta 168 filmsko obloženih tablet 200 filmsko obloženih tablet
Major bleeding and CRNM bleeding events occurred in 3 (0.41%) and 11 (1.50%) patients, respectively, in the apixaban group, compared to 6 (0.83%) and 13 (1.80%) patients in the heparin and/or VKA group.
Do večjih krvavitev in KPMK je prišlo pri 3 (0,41 %) oziroma 11 (1,50 %) bolnikih v skupini z apiksabanom v primerjavi s 6 (0,83 %) oziroma 13 (1,80 %) bolniki v skupini s heparinom in/ali AVK.
- if you have a prosthetic heart valve - if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned
če imate protetično srčno zaklopko če zdravnik ugotovi, da je vaš krvni tlak nestabilen, ali če za odstranitev krvnega strdka iz pljuč načrtuje drugo obliko zdravljenja ali kirurški poseg
14 film-coated tablets 20 film-coated tablets 28 film-coated tablets 56 film-coated tablets 60 film-coated tablets 100x 1 film-coated tablets 168 film-coated tablets 200 film-coated tablets
14 filmsko obloženih tablet 20 filmsko obloženih tablet 28 filmsko obloženih tablet 56 filmsko obloženih tablet 60 filmsko obloženih tablet 100 x 1 filmsko obložena tableta 168 filmsko obloženih tablet 200 filmsko obloženih tablet
Eliquis should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of bleeding.
Z uporabo zdravila Eliquis je treba prenehati najmanj 48 ur pred načrtovano operacijo ali invazivnimi postopki, pri katerih je prisotno zmerno ali veliko tveganje za krvavitve.
In studies conducted in healthy subjects, as described below, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, or atenolol.
V študijah, izvedenih pri zdravih osebah, apiksaban ni pomembneje spremenil farmakokinetike digoksina, naproksena ali atenolola.
These medicinal products may increase apixaban exposure by 2-fold (see section 4.5), or greater in the presence of additional factors that increase apixaban exposure (e.g., severe renal impairment).
Ta zdravila lahko izpostavljenost apiksabanu povečajo za 2-krat (glejte poglavje 4.5), v prisotnosti dodatnih dejavnikov, ki povečajo izpostavljenost apiksabanu (npr. huda okvara ledvic), pa tudi za več kot 2-krat.
Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa.
Apiksaban je močan, reverzibilen, neposreden in visoko selektiven zaviralec aktivnega mesta faktorja Xa za peroralno uporabo.
Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability (see section 5.1).
Pri pričakovanih terapevtskih odmerkih so spremembe vrednosti teh testov strjevanja krvi majhne in zelo spremenljive (glejte poglavje 5.1).
Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) The clinical program (AMPLIFY: apixaban versus enoxaparin/warfarin, AMPLIFY-EXT: apixaban versus placebo) was designed to demonstrate the efficacy and safety of apixaban for the treatment of DVT and/or PE (AMPLIFY), and extended therapy for the prevention of recurrent DVT and/or PE following 6 to 12 months of anticoagulant treatment for DVT and/or PE (AMPLIFY-EXT).
Zdravljenje GVT, zdravljenje PE in preprečevanje ponovne GVT ter PE (VTEt) Zasnovan je bil klinični program (AMPLIFY: primerjava apiksabana in enoksaparina/varfarina, AMPLIFY-EXT: primerjava apiksabana in placeba) za dokazovanje učinkovitosti in varnosti apiksabana pri zdravljenju GVT in/ali PE (AMPLIFY) ter pri podaljšanem zdravljenju za preprečevanje ponovitve GVT in/ali PE, ki je sledilo od 6- do 12-mesečnemu antikoagulacijskemu zdravljenju GVT in/ali PE (AMPLIFY-EXT).
Prior to initiating Eliquis, liver function testing should be performed.
Pred začetkom uporabe zdravila Eliquis je treba preveriti delovanje jeter.
It is unknown whether apixaban or its metabolites are excreted in human milk.
Ni znano, če se apiksaban ali njegovi presnovki izločajo v materino mleko.
Post-surgery treatment period Major
Obdobje zdravljenja po operaciji Večje
If you take more Eliquis than recommended, you may have an increased risk of bleeding.
Če ste vzeli večji odmerek zdravila Eliquis, kot bi smeli, se lahko poveča tveganje za krvavitve.
In this clinical trial, there was limited (2.1%) use of concomitant dual antiplatelet therapy.
V tem kliničnem preskušanju je bil delež sočasne uporabe dveh zaviralcev agregacije trombocitov omejen (2,1 %).
Intake with food does not affect apixaban AUC or Cmax at the 10 mg dose.
Hrana ne vpliva na vrednosti AUC ali Cmax 10 mg odmerka.
Alternatively, Eliquis tablets may be crushed and suspended in 60 mL of water or D5W and immediately delivered through a nasogastric tube (see section 5.2).
Druga možnost je, da tablete zdravila Eliquis zdrobimo in suspendiramo v 60 ml vode ali D5W in jih bolniku nemudoma damo preko nazogastrične sonde (glejte poglavje 5.2).
As with all new anticoagulant medicinal products, experience with neuraxial blockade is limited and extreme caution is therefore recommended when using apixaban in the presence of neuraxial blockade.
Kot pri drugih novih antikoagulantih je izkušenj z nevroaksialno blokado malo, zato je pri sočasni uporabi apiksabana in nevroaksialne blokade potrebna izjemna previdnost.
- Take the dose as soon as you remember and: - take the next dose of Eliquis at the usual time - then continue as normal.
Odmerek vzemite takoj, ko se spomnite in: naslednji odmerek zdravila Eliquis nato vzemite ob običajnem času.
The initiation of appropriate treatment, e.g., surgical haemostasis, the transfusion of fresh frozen plasma or the administration of a reversal agent for factor Xa inhibitors should be considered.
Razmisliti je treba o uvedbi ustreznega zdravljenja, npr. o kirurški hemostazi, transfuziji sveže zamrznjene plazme ali uporabi protiučinkovine za zaviralce faktorja Xa.
If you forget to take Eliquis
Če ste pozabili vzeti zdravilo Eliquis
If you take more Eliquis than you should
Če ste vzeli večji odmerek zdravila Eliquis, kot bi smeli
Electrical and/or pharmacologic cardioversion was conducted after at least 5 doses of 5 mg twice daily apixaban (or 2.5 mg twice daily in selected patients (see section 4.2)) or at least 2 hours after a 10 mg loading dose (or a 5 mg loading dose in selected patients (see section 4.2)) if earlier cardioversion was required.
Električno in/ali farmakološko kardioverzijo so opravili po vsaj 5 odmerkih apiksabana 5 mg dvakrat na dan (oziroma 2,5 mg dvakrat na dan pri izbranih bolnikih (glejte poglavje 4.2)) ali vsaj 2 uri po 10 mg polnilnem odmerku (oziroma 5 mg polnilnem odmerku pri izbranih bolnikih (glejte poglavje 4.2)), če je bilo treba kardioverzijo opraviti prej.